Stockscreener 앱 받기
3.23
2.12%
-0.07
시간 외 거래:
3.24
0.01
+0.31%
전일 마감가:
$3.30
열려 있는:
$3.28
하루 거래량:
46,737
Relative Volume:
0.45
시가총액:
$110.00M
수익:
-
순이익/손실:
$-12.48M
주가수익비율:
-8.2821
EPS:
-0.39
순현금흐름:
$-7.93M
1주 성능:
-3.00%
1개월 성능:
+25.68%
6개월 성능:
+39.22%
1년 성능:
+45.50%
1일 변동 폭
$3.22
$3.33
1주일 범위
$3.15
$3.45
52주 변동 폭
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
명칭
Anixa Biosciences Inc
전화
408-708-9808
주소
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
ANIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.23 | 110.00M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Maxim Group | Buy |
| 2022-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-12 | 개시 | H.C. Wainwright | Buy |
Anixa Biosciences Inc 주식(ANIX)의 최신 뉴스
Millennium Management LLC Acquires Shares of 11,028 Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 - Kilgore News Herald
Everything You Need to Know About the New Breast Cancer Vaccine - Vogue
Bank of America Corp DE Sells 6,891 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
3 Promising Penny Stocks With Market Caps Over $100M - simplywall.st
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage - GuruFocus
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage | ANIX Stock News - GuruFocus
Anixa Biosciences (ANIX) Maintains 'Buy' Rating with $10 Price T - GuruFocus
Anixa Biosciences (ANIX) Maintains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Gets Major Media Spotlight: How It Could Eradicate Cancer - Stock Titan
Anixa Biosciences (ANIX) to Present at ESMO Gynaecological Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation on Ovarian Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025 - MarketScreener
Breakthrough CAR-T Therapy for Ovarian Cancer: Anixa's Phase 1 Trial Results Coming at ESMO 2025 - Stock Titan
Jane Street Group LLC Purchases New Shares in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences (NASDAQ:ANIX) Upgraded by Wall Street Zen to Hold Rating - Defense World
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy - MSN
Kalkine Lists top companies in the nasdaq Featuring Innovative Biotech Like Anixa Biosciences - Kalkine Media
FY2025 EPS Forecast for Anixa Biosciences Boosted by Analyst - Defense World
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock - Investing.com Australia
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock By Investing.com - Investing.com Canada
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
H.C. Wainwright maintains Buy rating on Anixa Biosciences stock By Investing.com - Investing.com UK
Northern Trust Corp Trims Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview - GuruFocus
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled - Stock Titan
Anixa Biosciences (ANIX) Concludes Enrollment for Breast Cancer Vaccine Trial | ANIX Stock News - GuruFocus
Anixa Biosciences Announces Completion Of Enrollment In Phase 1 Trial Of Breast Cancer Vaccine - MarketScreener
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine - GuruFocus
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Vaccine Achieves Major Milestone: 70% of Patients Show Promising Immune Response - Stock Titan
ANIXA BIOSCIENCES Earnings Preview: Recent $ANIX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - marketscreener.com
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Tar - GuruFocus
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Anixa Biosciences Inc SEC 10-Q Report - TradingView
Anixa Biosciences (ANIX) Expected to Announce Earnings on Tuesday - Defense World
Anixa Biosciences CEO Provides Letter to Shareholders Outlining - GuruFocus
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones - Nasdaq
Breakthrough: Anixa's Cancer Vaccine Shows 70% Response Rate While CAR-T Therapy Extends Patient Survival - Stock Titan
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Stock Titan
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
Anixa Biosciences Inc (ANIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anixa Biosciences Inc 주식 (ANIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
| Titterton Lewis H jr | Director |
Jan 17 '25 |
Buy |
2.57 |
10,000 |
25,700 |
922,334 |
| KUMAR AMIT | Chief Executive Officer |
Jan 15 '25 |
Buy |
2.23 |
43,000 |
95,890 |
559,925 |
| Catelani Michael | President, COO, & CFO |
Jan 15 '25 |
Buy |
2.15 |
9,289 |
19,971 |
44,500 |
| Titterton Lewis H jr | Director |
Oct 22 '24 |
Option Exercise |
2.58 |
16,000 |
41,200 |
912,334 |
| Titterton Lewis H jr | Director |
Jul 30 '24 |
Buy |
3.06 |
21,646 |
66,237 |
890,754 |
0.39%
0.42%
자본화:
|
볼륨(24시간):